Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/caac.20121
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; http://dx.doi.org/10.1056/NEJMoa011954
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2008; 26:3543-51; PMID:18506025; http://dx.doi.org/10.1200/JCO.2007.15.0375
   PubMed Web of Science ®Google Scholar
• Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20:435-9; PMID:8533159; http://dx.doi.org/10.1016/S0968-0004(00)89095-7
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-8; PMID:15007088; http://dx.doi.org/10.1200/JCO.2004.07.173
   PubMed Web of Science ®Google Scholar
• Han B, Gao G, Wu W, Gao Z, Zhao X, Li L, Qiao R, Chen H, Wei Q, Wu J, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 2011; 72:238-43; PMID:20943283; http://dx.doi.org/10.1016/j.lungcan.2010.09.001
   PubMed Web of Science ®Google Scholar
• Pan J-H, Han J-X, Wu J-M, Huang H-N, Yu Q-Z, Sheng L-J. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2008; 78:49-55; PMID:18812689; http://dx.doi.org/10.1159/000158454
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao G, Li X, Ren S, Li A, Xu J, Zhang J, Zhou C. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PloS One 2012; 7:e48350; PMID:23118991; http://dx.doi.org/10.1371/journal.pone.0048350
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/science.1905840
   PubMed Web of Science ®Google Scholar
• Skaug V, Ryberg D, Arab EHKMO, Stangeland L, Myking AO, Haugen A. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6:1031-7; PMID:10741731
   PubMed Web of Science ®Google Scholar
• Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24:6728-41; PMID:15254240; http://dx.doi.org/10.1128/MCB.24.15.6728-6741.2004
   PubMed Web of Science ®Google Scholar
• Lalonde ME, Ouimet M, Lariviere M, Kritikou EA, Sinnett D. Identification of functional DNA variants in the constitutive promoter region of MDM2. Hum Genomics 2012; 6:15; PMID:23244604; http://dx.doi.org/10.1186/1479-7364-6-15
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, Zhou J, Wei Q, Zhang Z. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res: Official J Am Assoc Cancer Res 2008; 14:3633-40; PMID:18519798; http://dx.doi.org/10.1158/1078-0432.CCR-07-5155
   PubMed Web of Science ®Google Scholar
• Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602; PMID:15550242; http://dx.doi.org/10.1016/j.cell.2004.11.022
   PubMed Web of Science ®Google Scholar
• Dong J, Ren B, Hu Z, Chen J, Hu L, Dai J, Jin G, Xu L, Shen H. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinogenesis 2011; 50:433-8; PMID:21268124; http://dx.doi.org/10.1002/mc.20727
   PubMed Web of Science ®Google Scholar
• Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010; 10:88; PMID:20219101; http://dx.doi.org/10.1186/1471-2407-10-88
   PubMed Web of Science ®Google Scholar
• Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008; 113:799-807; PMID:18618574; http://dx.doi.org/10.1002/cncr.23668
   PubMed Web of Science ®Google Scholar
• Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28:2262-7; PMID:17827408; http://dx.doi.org/10.1093/carcin/bgm191
   PubMed Web of Science ®Google Scholar
• Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. HumMutat 2006; 27:110-7; PMID:16287156; http://dx.doi.org/10.1002/humu.20277
   PubMedGoogle Scholar
• Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer J Int Cancer 2006; 119:718-21; PMID:16496380; http://dx.doi.org/10.1002/ijc.21872
   PubMed Web of Science ®Google Scholar
• Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genetics 2003; 33:357-65; PMID:12567188; http://dx.doi.org/10.1038/ng1093
   PubMed Web of Science ®Google Scholar
• Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Du-rbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-73; PMID:20981092; http://dx.doi.org/10.1038/nature09534
   PubMed Web of Science ®Google Scholar
• Nancy P, Sakkaraiappan R, Vinay KJ. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer 2004; 6:79-82; PMID:15476592; http://dx.doi.org/10.1016/S1525-7304(11)70205-4
   PubMedGoogle Scholar
• Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010; 213:140-5; PMID:20189873; http://dx.doi.org/10.1016/j.ijheh.2010.01.004
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374(9699):1432-40; PMID:19767093; http://dx.doi.org/10.1016/S0140-6736(09)61497-5
   PubMed Web of Science ®Google Scholar
• Li CH, Liu MY, Liu W, Li DD, Cai L. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2014; 15 (2): 731-6; PMID:24568487; http://dx.doi.org/10.7314/APJCP.2014.15.2.731
   PubMed Web of Science ®Google Scholar
• Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006; 27:2028-33; PMID:16675470; http://dx.doi.org/10.1093/carcin/bgl047
   PubMed Web of Science ®Google Scholar
• Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer J Int Cancer 2006; 118:1275-8; PMID:16152608; http://dx.doi.org/10.1002/ijc.21463
   PubMed Web of Science ®Google Scholar
• Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005; 280:26776-87; PMID:15908423; http://dx.doi.org/10.1074/jbc.M505203200
   PubMed Web of Science ®Google Scholar
• Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics 2010; 10: 54-61; PMID:19786980
   PubMed Web of Science ®Google Scholar
• Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat 2012; 132: 947-53; PMID:21706156; http://dx.doi.org/10.1007/s10549-011-1637-5
   PubMed Web of Science ®Google Scholar
• Wang X, Wang YZ, Ma KW, Chen X, Li W. MDM2 rs2279744 and TP53 rs1042522 Polymorphisms Associated with Etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients. Oncol Res Treat 2014; 37(4): 176-80; PMID:24732641; http://dx.doi.org/10.1159/000360785
   PubMed Web of Science ®Google Scholar
• Xu B, Mi Y-Y, Min Z-C, Cheng G, Tong N, Tao J, Li P-C, Wang M-L, Tang J-L, Zhang Z-D. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol Ints 2010; 85:401-5; PMID:20664183; http://dx.doi.org/10.1159/000315991
   PubMed Web of Science ®Google Scholar
• Yong Y, Lin H. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15:97-8; PMID:15740637; http://dx.doi.org/10.1038/sj.cr.7290272
   PubMed Web of Science ®Google Scholar
• Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-9; PMID:14574645; http://dx.doi.org/10.1086/379378
   PubMed Web of Science ®Google Scholar